Skip to main content
< Back to news
Carolina Aguilar, CEO and co-founder of INBRAIN Neuroelectronics and Pablo Ortega, Machine Learning Lead. Foto / Microsoft
 10.11.2025

INBRAIN Neuroelectronics announces a collaboration with Microsoft to advance artificial intelligence in precision neurology

The company INBRAIN Neuroelectronics, based in the Barcelona Science Park, has announced the signing of a strategic collaboration agreement with Microsoft to drive the implementation of agentic artificial intelligence (Agentic AI), supported by Microsoft’s data and cloud infrastructure, with the aim of advancing real-time precision neurology and the development of next-generation brain-computer interface (BCI) therapeutics.

The collaboration will leverage Microsoft’s Azure AI infrastructure —including large language models (LLMs) applied to time-series data and advanced data analytics capabilities— to enable INBRAIN’s intelligent neural platform to continuously learn and adapt to each patient’s individual signals.

The agentic artificial intelligence approach, known as “Agentic AI”, allows AI systems to operate autonomously based on real-time data, representing significant potential to transform how neurological disorders are monitored and treated, offering closed-loop precision interventions for conditions such as Parkinson’s disease, epilepsy, and psychiatric or memory disorders in the future.

“Our vision is to create the most intelligent, autonomous, and personalized interface between the nervous system and artificial intelligence,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “By collaborating with Microsoft, we are combining our precision graphene neural technology with one of the world’s most powerful AI ecosystems. This partnership brings us closer to a future where brain-computer interfaces not only decode or modulate, but truly understand and respond to the nervous system in real time, turning the nervous system into the body’s operating system.”

Clare Barclay, President of Enterprise and Industry for EMEA at Microsoft, added: “This collaboration marks the next frontier of artificial intelligence. INBRAIN’s work sits at the intersection of neuroscience, bioelectronics, and AI, and we are proud to provide the data foundation and computational infrastructure that will help accelerate their mission to improve neurological health worldwide.”

INBRAIN’s neural platform is built on graphene, a single layer of carbon atoms known for its exceptional conductivity, biocompatibility, and precision. By integrating advanced decoding and modulation with agentic artificial intelligence, INBRAIN aims to develop a new class of AI-powered brain-computer interface therapeutics capable of personalized, data-driven modulation of neural circuits in real time, opening the door to organ-targeted therapies.

The collaboration builds on Microsoft’s ongoing investments in healthcare AI, cognitive modeling, and responsible data architectures, highlighting the shared commitment to ethical innovation and patient privacy in the development of medical technology in the field of neurology.

» Access to the news [+]